Controversies in pharmacotherapy of pain management

Lancet Oncology

Volumn 6, Issue 9, 2005, Pages 696-704

  Davis, Mellar P ^a   Walsh, Declan ^a   Lagman, Ruth ^a   LeGrand, Susan B ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; BUPIVACAINE; CARBAMAZEPINE; CELECOXIB; CLONIDINE; CYCLOOXYGENASE 2 INHIBITOR; DEXTROMETHORPHAN; FENTANYL; GABAPENTIN; HYDROMORPHONE; LIDOCAINE; LOCAL ANESTHETIC AGENT; MELOXICAM; METHADONE; MEXILETINE; MORPHINE; OPIATE; OXYCODONE; OXYMORPHONE; PHENYTOIN; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ANALGESIA; BONE PAIN; BREAST CANCER; CANCER PAIN; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG COST; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG PREFERENCE; DRUG SELECTIVITY; DRUG SYNTHESIS; EPIDURAL ABSCESS; GASTROINTESTINAL SYMPTOM; GRANULOMA; HALLUCINATION; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; INFECTION; LEG EDEMA; LIBIDO DISORDER; LIQUORRHEA; MEDICAL TECHNOLOGY; MENINGITIS; MYELOMA; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; PRURITUS; REVIEW; SEDATION; SOMNOLENCE;

ANALGESICS; ANALGESICS, OPIOID; BONE AND BONES; CYCLOOXYGENASE INHIBITORS; DIPHOSPHONATES; HUMANS; NEOPLASMS; NEURALGIA; PAIN;

EID: 24044500625     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70317-X     Document Type: Review

References (82)

1. GW Hanks F de Conno N Cherny et al. Morphine and alternative opioids in cancer pain: The EAPC recommendations Br J Cancer 95 2001 587-593
2. M Meldrum The ladder and the clock: Cancer pain and public policy at the end of the twentieth century J Pain Symptom Manage 29 2005 41-54
3. D Walsh Pharmacological management of cancer pain Semin Oncol 27 2000 45-63
4. E Bruera JL Palmer S Bosnjak et al. Methadone versus morphine as a first line strong opioid for cancer pain: A randomized, double blind study J Clin Oncol 22 2004 185-192
5. GR Lauretti GM Oliveria NL Pereira Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients Br J Cancer 89 2003 2027-2030
6. T Morita Y Tei S Inoue Agitated terminal delirium and association with partial opioid substitution and hydration J Palliat Med 6 2003 557-563
7. S Mercadante P Villari P Ferrera A Casuccio Addition of a second opioid may improve opioid response in cancer pain: Preliminary data Support Care Cancer 12 2004 762-766
8. TJ Smith PJ Coyne PS Staats et al. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive pain management (CMM) Ann Oncol 16 2005 825-833
9. MP Davis D Walsh R Lagman SB LeGrand Randomized clinical trial of an implantable drug delivery system J Clin Oncol 21 2003 2800-2806
10. C Ripamonti C Brunelli Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: Impact on pain, drug-related toxicity, and survival J Clin Oncol 21 2003 2801-2802
11. A Caraceni C Martini E Zecca et al. Breakthrough pain characteristics and syndromes in patients with cancer pain: An international survey Palliat Med 18 2004 177-183
12. A Dickman J Ellershaw NSAIDs: Gastroprotection or selective COX-2 inhibitor? Palliat Med 18 2004 275-286
13. S Mercadante RK Portenoy Opioid poorly responsive cancer pain, part 3: clinical strategies to improve opioid responsiveness J Pain Symptom Manage 21 2001 338-354
14. RE Coleman Bisphosphonates: Clinical experience Oncologist 9 (suppl 4) 2004 14-27
15. PW Mantyh Bone cancer pain: Mechanisms and potential therapies Prog Pain Res Manage 31 2004 259-278
16. F Saad GM Gleason R Murray et al. A randomized placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458-1468
17. D Walsh NI Rivera MP Davis et al. Strategies for pain management: Cleveland Clinic Foundation Guidelines for opioid dosing for cancer pain Support Cancer Ther 1 2004 157-164
18. G Pasternak Insights into mu opioid pharmacology the role of mu opioid receptor subtypes Life Sci 68 2001 2213-2219
19. I Gomes J Filipovska BA Jordan LA Devi Oligomerization of opioid receptors Methods 27 2002 358-365
20. E Bruera J Pereira S Watanabe et al. Opioid rotation in patients with cancer pain: A retrospective comparison of dose ratios between methadone, hydromorphone, and methadone Cancer 78 1996 852-857
21. C Quigley Hydromorphone for acute and chronic pain Cochrane Database Syst Rev 1 2002 CD003447
22. M Dean Opioids in renal failure and dialysis patients J Pain Symptom Manage 28 2004 497-504
23. E Bruera M Belzile E Pituskin et al. Randomized, double blind, crossover trial comparing safety an efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain J Clin Oncol 16 1998 3222-3229
24. E Kalso A Vainio Morphine and oxycodone hydrochloride in the management of cancer pain Clin Pharmacol Ther 47 1990 639-646
25. T Heiskanen E Kalso Controlled-release oxycodone and morphine in cancer related pain Pain 73 1997 37-45
26. Anon. Oral oxycodone: New preparation no better than oral morphine Prescribe Int 12 2003 83-84
27. A Berger M Smith L Lidsky et al. Opioid use and health care charges at the end of life in patients with metastatic disease cancer Manag Care Interface 17 2004 28-34
28. AJ Clark SH Ahmedzai LG Allan et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain Curr Med Res Opin 20 2004 1419-1428
29. R Van Seventer JM Smit RM Schipper et al. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain Curr Med Res Opin 19 2003 457-469
30. S Amhedzai D Brooks Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life J Pain Symptom Manage 13 1997 254-261
31. JO Wong GL Chiu CJ Tsao CL Chang Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain Acta Anaesthesiol Sin 35 1997 25-32
32. K Mystakidou E Tsilika E Parpa et al. Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl Int J Cancer 107 2003 486-492
33. ED Kharasch D Whittington C Hoffer Influence of herpetic and intestinal cytochrome P4503A activity of the acute disposition and effects or oral transmucosal fentanyl citrate Anesthesiology 101 2004 729-737
34. S Mercadante A Casuccio A Angello et al. Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home J Clin Oncol 16 1998 3656-3661
35. MP Davis D Walsh Methadone for relief of cancer pain: A review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration Support Care Cancer 9 2001 73-83
36. S Mercadante E Arcuri Opioids and renal function J Pain 5 2004 2-19
37. C Ripamonti M Bianchi The use of methadone for cancer pain Hematol Oncol Clin North Am 16 2002 543-555
38. DB Carr LC Goudas EM Balk et al. Evidence report on the treatment of pain in cancer patients J Natl Cancer Inst Monogr 32 2004 23-31
39. M Kloke Gaps and junctions between clinical experience and theoretical framework in the use of opioids Support Care Cancer 12 2004 749-751
40. M Von Zastrow A Svingos H Haberstock-Debic C Evans Regulated endocytosis of opioid receptors: Cellular mechanisms and proposed roles in physiological adaptation to opiate drugs Curr Opin Neurobiol 13 2003 348-353
41. C Chavkin JP McLaughlin JP Celver Regulation of opioid receptor function by chronic agonist exposure: Constitutive activity and desensitization Mol Pharmacol 60 2001 20-25
42. PJ Woolf JJ Linderman Untangling ligand induced activation of desensitization of G-protein-coupled receptors Biophys J 84 2003 3-13
43. SR George BF O'Dowd SP Lee G-protein-coupled receptor oligomerization and its potential for drug discovery Nat Rev Drug Discov 1 2002 808-820
44. EA Bolan RJ Tallarida GW Pasternak Synergy between μ and opioid ligands: Evidence for functional interactions among μ opioid receptor subtypes J Pharmacol Exp Ther 303 2002 557-562
45. M Grach W Massala D Pud et al. Can coadministration of oxycodone and morphine produce analgesic synergy in humans? An experimental cold pain study Br J Clin Pharmacol 58 2004 235-242
46. RD MacPherson The pharmacological basis of contemporary pain management Pharmacol Ther 88 2000 163-185
47. RH Enting WH Oldenmenger CDC van der Rijt et al. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids Cancer 94 2002 3049-3056
48. A Vaino I Tigerstedt Opioid treatment for radiating cancer pain: Oral administration vs epidural techniques Acta Anaesthesiol Scand 32 1988 179-185
49. P Sjogren A Banning Pain, sedation and reaction time during long-term treatment of cancer patients with oral and epidural opioids Pain 39 1989 5-11
50. E Kalso T Heiskanen M Rantio et al. Epidural and subcutaneous morphine in the management of cancer pain: A double-blind cross-over study Pain 67 1996 443-449
51. RL Rauck D Cherry MF Boyer et al. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain J Pain 4 2003 441-447
52. S Mercadante Controversies over spinal treatment in advanced cancer patients Support Care Cancer 6 1998 495-502
53. S Mercadante Problems with long-term spinal opioid treatment in advanced cancer patients Pain 79 1999 1-13
54. R Miguel Interventional treatment of cancer pain: The fourth step in the World Health Organization analgesic ladder? Cancer Control 7 2000 149-156
55. ES Krames Practical issues when using neuraxial infusion Oncology 13 (suppl 1) 1999 37-44
56. E Bruera T Schoeller R Wenk et al. A prospective multicenter assessment of the Edmonton staging system for cancer pain J Pain Symptom Manage 10 1995 348-355
57. SS Hwang VT Chang B Kasimis Cancer breakthrough pain characteristics and responses to treatment at a VA Medical Center Pain 101 2003 55-64
58. X Gomez-Batiste F Madrid F Moreno et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain J Pain Symptom Manage 24 2002 45-52
59. S Mercadante S Maddaloni S Roccella L Salvaggio Predictive factors in advanced cancer pain treated only by analgesics Pain 50 1992 151-155
60. S Mercadante L Radbruch A Caraceni et al. Episodic (breakthrough) pain Cancer 94 2002 832-839
61. Agency for Healthcare Research and Quality. Management of cancer pain summary. 2001; evidence report/technology assessment number 35, AHRQ publication number 01-E033.
62. JM Christie M Simmonds R Patt et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patient using transdermal fentanyl for persistent pain J Clin Oncol 16 1998 3238-3245
63. RK Portenoy R Payne P Coluzzi et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: A controlled dose titration study Pain 79 1999 303-312
64. DL Simmons RM Botting T Hla Cyclooxygenase isoenzymes: The biology of prostaglandin synthesis and inhibition Pharmacol Rev 56 2004 387-437
65. E Niederberger I Tegeder C Schafer et al. Opposites effects of rofecoxib on nuclear factor-κB and activating protein-1 activation J Pharmacol Exp Ther 304 2003 1153-1160
66. E Niederberger I Tegeder G Vetter et al. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-κB FASEB J 15 2001 1622-1624
67. K McCormack R Twycross Are COX-2 selective inhibitors effective analgesics? Pain Rev 8 2001 13-26
68. HS Smith W Baird Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population Am J Hosp Palliat Care 20 2003 297-306
69. PG Fine The role of rofecoxib, a cyclooxygenase-2 specific inhibitor, for the treatment of non-cancer pain: A review J Pain 3 2002 272-283
70. D Bouhassira N Attal Novel strategies for neuropathic pain In: L Villanueva A Dickenson H Ollat (eds.) Pain system in normal pathological states: A primer for clinicians 2004 H Ollat Liasp Press Seattle, WA 299-309
71. H McQuay A Moore Antidepressants in neuropathic pain H In: McQuay A Moore (eds) An evidence based resource for pain relief 1998 Oxford University Press Oxford 231-241
72. H McQuay A Moore Anticonvulsant drugs In: H McQuay A Moore (eds). An evidence based resource for pain relief 1998 Oxford University Press Oxford 221-230
73. RH Dworkin M Backonja MC Rowbotham et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations Arch Neurol 69 2003 1524-1534
74. A Beydoun MM Backonja Mechanistic stratification of antineuralgic agents J Pain Symptom Manage 25 (suppl 5) 2003 S18-S30
75. A Caraceni E Zecca C Bonezzi et al. Gabapentin for neuropathic cancer pain: A randomized controlled trial from the gabapentin cancer pain study group J Clin Oncol 22 2004 2909-2917
76. MA Sevcik NM Luger DB Mach et al. Bone cancer pain: The effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis Pain 111 2004 169-180
77. C Urch The pathophysiology of cancer-induced bone pain: Current understanding Palliat Med 18 2004 267-274
78. R Wong PJ Wiffen Bisphosphonates for the relief of pain secondary to bone metastases Cochrane Database Syst Rev 2 2004 1-127
79. A Heidenreich R Hoffman UH Engelmann The use of bisphosphonates for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer J Urol 165 2001 136-140
80. JJ Body I Mancini Bisphosphonates for cancer patients: Why, how and when? Support Care Cancer 10 2002 399-407
81. JJ Body IJ Diel R Bell et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer Pain 111 2004 306-312
82. A Heidenreich C Ohlmann JJ Body Ibandronate in metastatic bone pain Semin Oncol 31 (suppl 10) 2004 67-72